NHS England: Pharma transparency scheme ‘does not go far enough’

Generic  drugs

NHS England says pharma firms’ new transparency scheme ”does not go far enough” because it relies on voluntary disclosure by clinicians of payments received

You need to be an HSJ subscriber to read more


Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to hsj.co.uk
  • The HSJ app

Enquire about multi-user access